Novo Nordisk shows commercial recovery with accelerating patient additions in obesity and diabetes. Read why NVO stock is a hold. - Novo Nordisk shows commercial recovery with accelerating patient additions in obesity and diabetes, and strong initial traction for the Wegovy…
Authored By PTI | Published at: Nov 5, 2026 10:37 AM IST New Delhi: Aurobindo Pharma Ltd on Wednesday reported a 32.5 per cent increase in net profit to Rs 1,123.84 crore during the September quarter, driven by growth across key businesses. The pharma major had…
TradingView Key facts: Amgen Q3 beat; guidance raised; trials succeed; targets rise - Amgen (AMGN) reported Q3 revenue of $10.37 billion, up 8%, and adjusted EPS of $6.45, up 14% and above forecasts. It raised 2025 revenue and adjusted EPS guidance. - Amgen reported positive Phase 3 results for TEZSPIRE…
Pfizer remains a Buy as its robust pipeline and strategic acquisitions drive portfolio adaptation ahead of the LOE cliff. Learn more about PFE stock here. - Pfizer remains a Buy as its robust pipeline and strategic acquisitions drive portfolio adaptation ahead…
Gilead Faces A Lower Medicare Price For Biktarvy CMS sets the Medicare price for Biktarvy, Gilead’s largest product. During its October 29, 2026 earnings call, management said the agency set the drug’s Medicare price at $2,600 per 30-day supply, or about 38% below the…
Boehringer is turning to China for cancer research in a multibillion-dollar deal with Sino Biopharmaceutical. Six preclinical programs involving antibody-drug conjugates (ADCs) and T-cell engagers are expected to strengthen its oncology pipeline. Boehringer will initially pay $358 million, with up to…
Kelowna, British Columbia – November 4, 2026 – TheNewswire - Lexaria Bioscience Corp. LEXX (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an unnamed pharmaceutical company (“PharmCo”) to investigate Lexaria’s DehydraTECH technology with…
By Sabrina Valle, Milana Vinn and Amy-Jo Crowley Nov 4 (Reuters) – AstraZeneca made an offer of about $10 billion to acquire obesity drugmaker Rhythm Pharmaceuticals, according to three people familiar with the matter. AstraZeneca offered as much as $134 a share in the…
Nxera Licenses EP4 Agonist to AbbVie | PharmExec Pharmaceutical Executive Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal…
TradingView Key facts: Merck Q3 Sales Up, EPS Down; Approvals; $550M Boost - Merck (MRK) reported third-quarter 2026 sales of $18.09 billion, up 4.7% year over year. Net income fell 12.4% to $5.07 billion, and diluted EPS declined 12.1% to $2.04. - Merck & Co., Inc. (MRK) received U.S. approvals for Lipfendra and…
Drugmakers as businesses: Eli Lilly, Novo Nordisk, Pfizer, Merck, J&J, AbbVie, AstraZeneca and India's pharma firms - results, pipelines, deals and leadership.
An article joins this feed when it matches these terms. Each one is also a search of its own.